CDX 7108
Alternative Names: CDX-7108Latest Information Update: 28 Nov 2024
At a glance
- Originator Codexis; Nestle Health Science
- Developer Nestle Health Science
- Class Enzymes
- Mechanism of Action Enzyme replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Exocrine pancreatic insufficiency
Most Recent Events
- 28 Nov 2024 No recent reports of development identified for phase-I development in Exocrine-pancreatic-insufficiency(In volunteers) in Australia (PO)
- 28 Nov 2024 No recent reports of development identified for phase-I development in Exocrine-pancreatic-insufficiency(In volunteers) in New Zealand (PO)
- 28 Feb 2024 No recent reports of development identified for preclinical development in Gastrointestinal-disorders in USA (PO)